Skip to main content
. Author manuscript; available in PMC: 2012 May 20.
Published in final edited form as: FEBS Lett. 2011 Mar 21;585(10):1412–1426. doi: 10.1016/j.febslet.2011.03.021

Fig.6. Orexin release is necessary for the endogenous rise in glucose appearance at dusk in nocturnal animals.

Fig.6

The endogenous rise in glucose appearance (Ra) during ICV vehicle administration is shown in the left panel. ICV administration of the orexin antagonist, during the latter part of the light period, prevents the endogenous rise of Ra before the onset of darkness (ZT11–ZT12), and during the onset of the dark period (ZT12–ZT15) (right panel). The orexin antagonist SB-408124 was administered ICV from ZT4 – ZT12. IV administration of the orexin antagonist had no effect on glucose appearance. Food intake was not changed by ICV orexin. O and Δ, P<0.05 compared with ZT4–6 and ZT6–11, respectively. *, P<0.05 compared with comparable time points in the vehicle group.